Micreos
Business Services · Switzerland · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Neuhofstrasse 12, Baar, Zug, 6340, Switz...Phone Number
+31 888007100Website
www.micreos.comRevenue
$15.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Micreos
Micreos is a biotech company based in Zug, Switzerland, focused on the discovery and development of recombinant proteins for chronic dermatology conditions, particularly Atopic Dermatitis. Their innovative engineered endolysin technology effectively eliminates harmful pathogens like Staphylococcus aureus, which exacerbates skin conditions, while preserving the skin's natural microbiome. With a commitment to addressing significant unmet medical needs, Micreos aims to enter clinical trials for their lead molecule, MEndoB, in late 2026. The company seeks collaboration with partners who share their vision of revolutionizing dermatological treatments.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Micreos your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Micreos
Check out if Micreos is spiking on competitors!
Click to see if Micreos had a recent Job posting/layoffs
Product Launch: Get notified when Micreos launches new products
Earning: See what the market has to say on Micreos recently announced quarterly report
Micreos, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Micreos has new funding data
Check if Micreos has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Micreos as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Micreos is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Micreos is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Micreos.
Micreos financials insights
Gather financial insights about Micreos, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Private Equity
$13.4M
2019
Unspecified
$33.8M
2021
Unspecified
$37.1M
2022
Other Financing Round
$24.4M
Micreos Tech Stack
A closer look at the technologies used by Micreos
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Project
A high-level source in Medical & Health has indicated that the organization is planning to release a request for proposal (RFP) for initiatives related to patient engagement.
Request for Proposal (RFP), Customer Engagement
Project
A high-level source in Medical & Health has indicated that the organization is planning to release a request for proposal (RFP) for initiatives related to patient data.
Request for Proposal (RFP), Clinical Systems, Data Management, Information Governance
Funding
New Hire
Executive Move
Micreos News & Media
Investigational study provides evidence that recombinant endolysin XZ.700* is a promising novel non-antibiotic treatment strategy aimed at controlling Staphylococcus aureus (S. aureus) colonization of lesional skin in Cutaneous T-cell lymphoma (CTCL).
Research shows XZ.700* could block tumor promoting effects of S. aureus on malignant T cells, potentially delaying tumor progression. Findings strengthen potential of Micreos' endolysin technology to address unmet patient needs in treating CTCL in the wake of devastating antimicrobial...Micreos’ Alternative to Antibiotics Secures Next €25 Million
THE HAGUE, The Netherlands--(BUSINESS WIRE)-- #AMR--Dutch/Swiss biotech company Micreos announced today it has secured its next funding round of €25 million in growth capital and for clinical development of its endolysin technology platform, set to replace antibiotics in many areas. This technology enables - for the first time - targeted killing of only the unwanted bacteria, regardless of resistance. The funding comprises growth capital for Gladskin, the company’s specialized skincare brand, foMicreos Pharmaceuticals announces success of its XZ.700 technology in selectively eliminating Staphylococcus aureus pathogen without triggering resistance
In a new publication, the company's flagship compound proves effective in targeting the harmful pathogen while preserving a healthy microbiome ZUG, Switzerland, April 14, 2022 /PRNewswire/ -- Micreos Pharmaceuticals today announces findings from a study proving the effectiveness of...Micreos Pharmaceuticals Welcomes Trine Ahlgreen and Carsten Edwards to Its Executive Team to Accelerate Its Next Phase of Development
ZUG, Switzerland--(BUSINESS WIRE)-- #AMR--Micreos welcomes Trine Ahlgreen and Carsten Edwards to its Executive team to accelerate the development of its alternatives to traditional antibiotics
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Micreos
Sign Up For FreeTo access detailed company insights
Micreos is a biotech company based in Zug, Switzerland, focused on the discovery and development of recombinant proteins for chronic dermatology conditions, particularly Atopic Dermatitis. Their innovative engineered endolysin technology effectively eliminates harmful pathogens like Staphylococcus aureus, which exacerbates skin conditions, while pr... Read More
